泸州医学院学报
瀘州醫學院學報
로주의학원학보
JOURNAL OF LUZHOU MEDICAL COLLEGE
2013年
3期
237-240
,共4页
赵龙%喻玉%刘蔚%杨伟兴%陈辉%李丽%向未%肖国辉
趙龍%喻玉%劉蔚%楊偉興%陳輝%李麗%嚮未%肖國輝
조룡%유옥%류위%양위흥%진휘%리려%향미%초국휘
胰瘅1号%胰瘅2号%胰瘅贴%重症急性胰腺炎%CRP%Ca2+
胰癉1號%胰癉2號%胰癉貼%重癥急性胰腺炎%CRP%Ca2+
이단1호%이단2호%이단첩%중증급성이선염%CRP%Ca2+
YIDan 1%YIDan 2%YIDan TIE%Severe acute pancreatitis,CRP%Ca2+
目的:通过观察胰瘅1号、胰瘅2号、胰瘅贴综合治疗对重症急性胰腺炎(severe acute pancreatitis,SAP)患者血清CRP及Ca2+影响,探讨其疗效。方法:依据纳入和排除标准,选取我院中西医结合科收治的SAP 40例,随机分为对照组和治疗组,对照组予以西医基础治疗,治疗组在西医基础上加用胰瘅1号、胰瘅2号、胰瘅贴综合治疗。观察患者血清CRP及Ca2+第1d、第3d、第7d、第14d变化。结果:治疗前后Ca2+在治疗组与对照组间无明显差别(P>0.05),但治疗组CRP从入院第3d开始较对照组明显下降(P<0.05)。结论:胰瘅1号、胰瘅2号、胰瘅贴综合治疗可能通过抑制炎症途径从而有效降低重症急性胰腺炎患者血清CRP水平。
目的:通過觀察胰癉1號、胰癉2號、胰癉貼綜閤治療對重癥急性胰腺炎(severe acute pancreatitis,SAP)患者血清CRP及Ca2+影響,探討其療效。方法:依據納入和排除標準,選取我院中西醫結閤科收治的SAP 40例,隨機分為對照組和治療組,對照組予以西醫基礎治療,治療組在西醫基礎上加用胰癉1號、胰癉2號、胰癉貼綜閤治療。觀察患者血清CRP及Ca2+第1d、第3d、第7d、第14d變化。結果:治療前後Ca2+在治療組與對照組間無明顯差彆(P>0.05),但治療組CRP從入院第3d開始較對照組明顯下降(P<0.05)。結論:胰癉1號、胰癉2號、胰癉貼綜閤治療可能通過抑製炎癥途徑從而有效降低重癥急性胰腺炎患者血清CRP水平。
목적:통과관찰이단1호、이단2호、이단첩종합치료대중증급성이선염(severe acute pancreatitis,SAP)환자혈청CRP급Ca2+영향,탐토기료효。방법:의거납입화배제표준,선취아원중서의결합과수치적SAP 40례,수궤분위대조조화치료조,대조조여이서의기출치료,치료조재서의기출상가용이단1호、이단2호、이단첩종합치료。관찰환자혈청CRP급Ca2+제1d、제3d、제7d、제14d변화。결과:치료전후Ca2+재치료조여대조조간무명현차별(P>0.05),단치료조CRP종입원제3d개시교대조조명현하강(P<0.05)。결론:이단1호、이단2호、이단첩종합치료가능통과억제염증도경종이유효강저중증급성이선염환자혈청CRP수평。
Objective: To study the effect of YIDan 1, YIDan 2,and YIDanTIE on the levels of CRP and Ca2+in severe acute pancreatitis, and to investigate their therapeutic effect.Methods: 40 cases of strictly selected SAP were randomly divided into treatment group and control group. The treatment group received conventional therapy as well as YIDan 1, YIDan 2, and YIDanTIE. The levels of CRP and Ca2+were determined on day 1,3,7 and 14. Results:No significant differences were noted in the level of Ca2+ between control group and treatment group (P>0.05),while the level of CRP began to decrease from the third day (P<0.05).Conclusion: Comprehensive treatment of YIDan 1, YIDan 2,and YIDan TIE in severe acute pancreatitis may apparently decrease the CRP level by inhibiting the inflammatory pathways.